Abstract: Background: Despite advances in assisted reproductive technologies (ART), approximately 60% of cases fail to achieve clinical pregnancy. Poor ovarian response and age-related decline in oocyte quality pose significant challenges for women undergoing
in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), thereby hindering the success of these procedures. These challenges underscore the need for effective pre-treatment strategies, such as coenzyme Q10 (CoQ10) supplementation, to improve ART outcomes. This study aims to evaluate the effect of pre-treatment with CoQ10 300 mg BID, an antioxidant and mitochondrial energizer, on improving the number of high-quality embryo, ovarian response to stimulation, fertilization and pregnancy rate in infertile women undergoing IVF/ICSI.
Method: This was a multicentre, prospective, observational, single-arm, real-world evidence study in which infertile women undergoing IVF/ICSI based on physician assessment were instructed to take CoQ10 300 mg capsule twice daily for 2-3 months before beginning their ART cycles. Primary outcome measure was the number high-quality day-3 embryo. Secondary outcome measures included number of oocytes retrieved, fertilization rate and clinical pregnancy rate. Adverse events were monitored throughout the trial.
Results: A total of 1061 eligible patients were included in this study. Pre-treatment with CoQ10 300 mg twice daily for an average duration of 74 days yielded significant results. The number of high-quality day-3 embryos per cycle was 5 (interquartile range [IQR] = 3-7), while the number of retrieved oocytes per cycle was 8 (IQR = 6-10). The mean fertilization rate was found to be 73% ± 0.17, and clinical pregnancy was achieved in 874 patients, resulting in a clinical pregnancy rate of 82.53%. Importantly, no adverse events leading to the discontinuation of treatment were reported, underscoring the safety and tolerability of CoQ10 300 mg BID pre-treatment.
Conclusion: The findings suggest that pre-treatment with CoQ10 300 mg twice daily significantly improves embryo quality, oocyte yield, fertilization success, and clinical pregnancy rates in infertile women undergoing IVF/ICSI. These results provide important insights into the potential benefits of CoQ10 300 mg BID for enhancing response to ovarian stimulation protocols and improving overall IVF/ICSI outcomes.
Indexed in Index Copernicus
